LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,691 | -12.7% | 19,230 | +4.4% | 0.00% | – |
| Q2 2023 | $25,981 | -8.1% | 18,426 | -2.3% | 0.00% | – |
| Q1 2023 | $28,281 | +26.7% | 18,854 | -1.1% | 0.00% | – |
| Q4 2022 | $22,315 | +1.4% | 19,073 | -0.0% | 0.00% | – |
| Q3 2022 | $22,000 | -38.9% | 19,080 | -15.8% | 0.00% | – |
| Q2 2022 | $36,000 | +33.3% | 22,651 | +1.1% | 0.00% | – |
| Q1 2022 | $27,000 | -53.4% | 22,410 | -4.8% | 0.00% | – |
| Q4 2021 | $58,000 | -4.9% | 23,539 | -2.4% | 0.00% | – |
| Q3 2021 | $61,000 | -12.9% | 24,113 | -1.7% | 0.00% | – |
| Q2 2021 | $70,000 | +27.3% | 24,527 | +4.8% | 0.00% | – |
| Q1 2021 | $55,000 | +31.0% | 23,394 | -3.0% | 0.00% | – |
| Q4 2020 | $42,000 | +100.0% | 24,122 | +5.4% | 0.00% | – |
| Q3 2020 | $21,000 | 0.0% | 22,889 | -5.4% | 0.00% | – |
| Q2 2020 | $21,000 | -50.0% | 24,183 | -51.5% | 0.00% | – |
| Q1 2020 | $42,000 | +68.0% | 49,820 | +92.6% | 0.00% | – |
| Q3 2019 | $25,000 | – | 25,867 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
| Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
| Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
| Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
| DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
| Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
| Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
| Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
| MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |